Current Issue : November/December 2011
Web Exclusives
Lois E. Lamerato, PhD; Eric J. Kruep, PharmD; Susan L. Hogue, PharmD; Sham L. Chaudhari, MS; and Michael T. Eaddy, PharmD, PhD
Early rather than later initiation of 5ARI therapy reduced the likelihood of clinical progression in benign prostatic hyperplasia patients and offers substantial savings to health plans.
Maryna Marynchenko, MBA; Andrew P. Yu, PhD; Veronique Lauzon, MSc; Karthik Ramakrishnan, MPH; Eric Q. Wu, PhD; Rym Ben-Hamadi, MSc; Steven I. Blum, MBA; Moshe Haim Erder, PhD; and Anjana Bose, PhD
Switching from generic selective serotonin reuptake inhibitor therapy to escitalopram is more cost-effective than switching to venlafaxine or duloxetine in major depressive disorder patients.
Robert A. Bailey, MD, FASN; Heidi C. Waters, MS, MBA; Frank R. Ernst, PharmD, MS; Bernadette H. Johnson, MBA; and R. Scott McKenzie, MD
When administered in real-world hospital outpatient settings, infliximab dosing patterns in patients with Crohn’s disease emain relatively stable, with minimal dose escalation occurring.
Jonathan H. Watanabe, PharmD, MS; and John P. Ney, MD
The efficacy of once-daily dose generic oxybutynin extended release is comparable to other anticholinergics used for overactive bladder.
Dominick Esposito, PhD; Peter Wahl, MLA, MS; Gregory W. Daniel, PhD, RPh, MS, MPH; Michael A. Stoto, PhD; and Thomas W. Croghan, MD
We found a small difference in total costs for escitalopram initiators. Its impact on health plan budgets is unknown.
Supplements
Advertisement
Advertisement
